Tumor counterattack - Concept and reality

European Journal of Immunology

Volumn 30, Issue 3, 2000, Pages 725-731

  Igney, Frederik H ^a   Behrens, Christian K ^a,b   Krammer, Peter H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Axaron Bioscience AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; CANCER IMMUNOLOGY; CELL INFILTRATION; CYTOKINE PRODUCTION; EYE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GRAFT REJECTION; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TESTIS CELL; TUMOR; TUMOR CELL;

ANIMALS; ANTIGENS, CD95; FAS LIGAND PROTEIN; GRAFT REJECTION; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUTROPHILS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0033993449     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200003)30:3<725::AID-IMMU725>3.0.CO;2-D     Document Type: Review

References (74)

1. Peter, M. E. and Krammer, P. H., Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 1998. 10: 545-551.
2. Scaffidi, C., Kirchhoff, S., Krammer, P. H. and Peter, M. E., Apoptosis signaling in lymphocytes. Curr. Opin. Immunol. 1999. 11: 277-285.
3. Krammer, P. H., CD95 (APO-1/Fas)-mediated Apoptosis: Live and Let Die. Adv. Immunol. 1999. 71: 162-210.
4. French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C. and Tschopp, J., Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 1996. 133: 335-343.
5. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R. and Ferguson, T. A., Fas-ligand-induced apoptosis as a mechanism of immune privilege. Science 1995. 279: 1189-1192.
6. Stuart, P. M., Griffith, T. S., Usui, N., Pepose, J., Yu, X. and Ferguson, T. A., CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 1997. 99: 396-402.
7. Griffith, T. S., Yu, X., Herndon, J. M., Green, D. R. and Ferguson, T. A., CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996. 5: 7-16.
8. Gao, Y., Herndon, J. M., Zhang, H., Griffith, T. S. and Ferguson, T. A., Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J. Exp. Med. 1998. 188: 887-896.
9. Bellgrau, D., Gold, D., Selawry, H., Moore, H., Franzusoff, A. and Duke, R. C., A role for CD95 ligand in preventing graft rejection. Nature 1995. 377: 630-632.
10. Allison, J., Georgiou, H. M., Strasser, A. and Vaux, D. L., Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 1997. 94: 3943-3947.
11. Hunt, J. S., Vassmer, D., Ferguson, T. A. and Miller, L., Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J. Immunol. 1997. 158: 4122-4128.
12. Rogers, A. M., Boime, I., Connolly, J., Cook, J. R. and Russell, J. H., Maternal-fetal tolerance is maintained despite transgene-driven trophoblast expression of MHC class I, and defects in FAs and its ligand. Eur. J. Immunol. 1998. 28: 3479-3487.
13. Phillips, T. A., Ni, J., Pan, G., Ruben, S. M., Wei, Y.-F., Pace, J. L. and Hunt, J. S., TRAIL (Apo-2L) and TRAIL Receptors in human placentas: Implications for immune privilege. J. Immunol. 1999. 162: 6053-6059.
14. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A.-L., Schnuriger, V., Perrin, G., French, L., van Meir, E. G., de Tribolet, N., Tschopp, J. and Dietrich, P.-Y., Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 1997. 99: 1173-1178.
15. Choi, C., Park, J. Y., Lee, J., Lim, J.-H., Shin, E.-C., Ahn, Y. S., Kim, C.-H., Kim, S.-J., Kim, J.-D., Choi, I. S. and Choi, I.-H., Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ. J. Immunol. 1999. 162: 1889-1895.
16. Sabelko, K. A., Kelly, K. A., Nahm, M. H., Cross, A. H. and Russell, J. H., Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 1997. 159: 3096-3099.
17. Lau, H. T., Yu, M., Fontana, A. and Stoeckert, C. J. J., Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996. 273: 109-112.
18. Kang, S.-M., Hofmann, A., Le, D., Springer, M. L, Stock, P. G. and Blau, H., Immune response and myoblasts that express Fas ligand. Science 1997. 278: 1322-1324.
19. Li, X.-K., Okuyama, T., Tamura, A., Enosawa, S., Kaneda, Y., Takahara, S., Funashima, N., Yamamda, M., Amemiya, H. and Suzuki, S., Prolonged survival of rat liver allografts transfected with Fas ligand expressing plasmid. Transplantation 1998. 66: 1416-1423.
20. Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H. and Galle, P. R., Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 1997. 99: 403-413.
21. Fulda, S., Sieverts, H., Friesen, C., Herr, I. and Debatin, K.-M., The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997. 57: 3823-3829.
22. Friesen, C., Herr, I., Krammer, P. H. and Debatin, K.-M., Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 1996. 2: 574-577.
23. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K. and Shanahan, F., The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 1998. 160: 5669-5675.
24. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Roche, D., Brady, C., Kelly, J., Collins, J. K. and Shanahan, F., Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999. 44: 156-162.
25. Gratas, C., Thoma, Y., van Meir, E. G., Klein, M., Tenan, M., Ishii, N., Tachibana, O., Kleihues, P. and Ohgaki, H., Fas ligand expression in gliobastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997. 7: 863-869.
26. Gutierrez-Steil, C., Wrone-Smith, T., Sun, X., Krueger, J. G., Coven, T. and Nickoloff, B. J., Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J. Clin. Invest. 1998. 101: 33-39.
27. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schreier, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. and Tschopp, J., Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 1996. 274: 1363-1366.
28. Kume, T., Oshima, K., Yamashita, Y., Shirakusa, T. and Kikuchi, M., Relationship between Fas-ligand expression or carcinoma cell and cytotoxic T-lymphocyte responses in lympho-epithelioma-like cancer of the stomach. Int. J. Cancer 1999. 84: 339-343.
29. Mariani, S. M. and Krammer, P. H., Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 1998. 28: 973-982.
30. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R. and Kratzke, R. A., Human lung carcinoma express Fas ligand. Cancer Res. 1997. 57: 1007-1012.
31. O'Connell, J., O'Sullivan, G. C., Collins, J. K. and Shanahan, F., The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996. 184: 1075-1082.
32. O'Connell, J., Bennett, M. W., O'Sullivan, G. C., Roche, D., Kelly, J., Collins, J. K. and Shanahan, F., Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 1998. 186: 240-246.
33. Peduto Eberl, L., Guillou, L., Saraga, E., Schröter, M. and French, L. E., Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int. J. Cancer 1999. 81: 772-778.
34. Rabinowich, H., Reichert, T. E., Kashii, Y., Gastman, B. R., Bell, M. C. and Whiteside, T. L., Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. J. Clin. Invest. 1998. 101: 2579-2588.
35. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J. and Takahashi, H., Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 1997. 94: 6420-6425.
36. Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, T., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H. and Galle, P. R., Lymphocyte apoptosis induced by CD95 (APO-1/ Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med. 1996. 2: 1361-1366.
37. Ungefroren, H., Voss, M., Jansen, M., Roeder, C., Henne-Bruns, D., Kremer, B. and Kalthoff, H., Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 1998. 58: 1741-1749.
38. Villunger, A., Egle, A., Marschitz, l., Kos, M., Böck, G., Ludwig, H., Geley, S., Kofler, R. and Greil, R., Constitutive expression of Fas (Apo-1/CD95)-ligand in multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997. 90: 12-20.
39. Zeytun, A., Hassuneh, M., Nagarkatti, M. and Nagarkatti, P., Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street. Blood 1997. 90: 1952-1959.
40. Walker, P. R., Saas, P. and Dietrich, P.-Y., Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 1998. 10: 564-572.
41. Khar, A., Varalakshmi, C., Pardhasaradhi, B. V. V., Mubarak Ali, A. and Leela Kumari, A., Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: A mechanism of immune evasion. Cell. Immunol. 1998. 189: 85-91.
42. Nishimatsu, H., Takeuchi, T., Ueki, T., Kajiwara, T., Moriyama, N., Ishida, T., Li, B., Kakizoe, T. and Kitamura, T., CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol. Immunother. 1999. 48: 56-61.
43. Arai, H., Chan, S. Y., Bishop, D. K. and Nabel, G. J., Inhibition of the alloantibody response by CD95 ligand. Nature Med. 1997. 8: 843-848.
44. Krammer, P. H., The tumor strikes back: New data on expression of the CD95 (APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death Differ. 1997. 4: 362-364.
45. Kang, S.-M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G. and Baekkeshov, S., Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 1997. 3: 738-743.
46. Judge, T. A., Desai, N. M., Yang, Z., Rostami, S., Alonso, L., Zhang, H., Chen, Y., Markman, J. F., DeMateo, R. P., Barker, C. F., Naji, A. and Turka, L. A., Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation 1998. 66: 426-434.
47. Takeuchi, T., Ueki, T., Nishimatsu, H., Kajiwara, T., Ishida, T., Jishage, K.-I., Ueda, O., Suzuki., H., Li, B., Moriyama, N. and Kitamura, T., Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 1997. 162: 518-522.
48. Seino, K.-I., Kayagaki, N., Okumura, K. and Yagita, H., Antitumor effect of locally produced CD95 ligand. Nature Med. 1997. 3: 165-170.
49. Shimizu, M., Fontana, A., Takeda, Y., Yagita, H., Yoshimoto, T. and Matsuzawa, A., Induction of antitumor immunity with Fas/Apo-1 ligand (CD95L)-transfected neuroblastoma Neuro-2a cells. J. Immunol. 1999. 162: 7350-7357.
50. Okamoto, S., Takamizawa, S., Bishop, W., Wen, J., Kimura, K. and Sandler, A., Overexpression of Fas ligand does not confer immune privilege to a pancreatic β tumor cell line (βTC-3). J. Surg. Res. 1999. 84: 77-81.
51. Yagita, H., Seino, K.-I., Kayagaki N. and Okumura, K., CD95 ligand in graft rejection. Nature 1996. 379: 682.
52. Drozdzik, M., Qian, C., Lasarte, J. J., Bilbao, R. and Prieto, J., Antitumor effect of allogenic fibroblasts engineered to express Fas ligand. Gene Therapy 1998. 5: 1622-1630.
53. Arai, H., Gordon, D., Nabel, E. G. and Nabel, G. J., Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 1997. 94: 3862-3867.
54. Miwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S. and Suda, T., Caspase 1-independent 1L-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nature Med. 1998. 4: 1287-1292.
55. Seino, K.-I., Iwabuchi, K., Kayagaki, N., Miyata, R., Nagaoka, I., Matsuzawa, A., Fukao, K., Yagita, H. and Okumura, K., Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 1998. 161: 4484-4488.
56. Ottonello, L., Tortolina, G., Amelotti, M. and Dallegri, F., Soluble Fas ligand is chemotactic for human neutrophilic polymorphoclear leukocytes. J. Immunol. 1999. 162: 3601-3606.
57. Ehl, S., Hoffmann, Rohrer, U., Nagata, S., Hengartner, H. and Zinkernagel, R., Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 1996. 156: 2357-2360.
58. Klas, C., Debatin, K.-M., Jonker, R. R. and Krammer, P. H., Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 1993. 5: 625-630.
59. Seino, K.-I., Kayagaki, N., Tsukada, N., Fukao, K., Yagita, H. and Okumura, K., Transplantation of CD95L-expression grafts. Transplantation 1997. 7: 1050-1054.
60. Chen, J.-J., Sun, Y. and Nabel, G. J., Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998. 282: 1714-1717.
61. Huber, D., Philipp, J. and Fontana, A., Protease inhibitors interfere with the transforming growth factor-β-dependent but not the transforming growth factor-β-independent pathway of tumor cell-mediated immunosuppression. J. Immunol. 1992. 148: 277-284.
62. Mariani, S. M., Matiba, B., Bäumler, C. and Krammer, P. H., Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 1995. 25: 2303-2307.
63. Tanaka, M., Suda, T., Takahashi, T. and Nagata, S., Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 1995. 14: 1129-1135.
64. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A. H. and Nagata, S., Fas ligand in human serum. Nature Med. 1996. 2: 317-322.
65. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K. and Yagita, H., Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995. 182: 1777-1783.
66. Gainer, A., Suarez-Pinzon, W., Min, W.-P., Swiston, J. R., Hancock-Friesen, C., Korbutt, G. S., Rajotte, R. V., Warnock, G. L. and Elliott, J. F., Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-lg or soluble Fas ligand. Transplantation 1998. 66: 194-199.
67. Suda, T., Tanaka, M., Miwa, K. and Nagata, S., Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 1996. 167: 3918-3924.
68. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T. and Nagata, S., Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997. 186: 2045-2050.
69. Tanaka, M., Itai, T., Adachi, M. and Nagata, S., Downregulation of Fas ligand by shedding. Nature Med. 1998. 4: 31-36.
70. Schneider, P., Holler, N., Bodmer, J. L., Hahne, M., Frei, K., Fontana, A. and Tschopp, J., Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of the proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998. 187: 1205-1213.
71. Kayagaki, N., Yamaguchi, N., Nagao, F., Matsuo, S., Maeda, H., Okumura, K. and Yagita, H., Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. USA 1997. 94: 3914-3919.
72. Suzuki, I. and Fink, P. J., Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 1998. 187: 123-128.
73. + T cells. Nature Med. 1998. 4: 1377-1382.
74. Nagata, S., Apoptosis by death factors. Cell 1997. 88: 355-365.